



PR01 Oncolytic adenoviruses expressing metabolic targets can improve viro-immunotherapy with bispecific T cell engagers through reducing acidosis in an in vitro model. Arthur Dyer, University of Oxford, Oxford, United Kingdom.

PR02 The co-expression of VISTA and TIGIT on cytotoxic T cells defines subpopulation with altered immunometabolism. Cassandra Gilmour, Cleveland Clinic Foundation, Cleveland, OH, United States.

PR06 Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

PR08 Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer. Abigail E. Overacre-Delgoffe, University of Pittsburgh, Pittsburgh, PA, United States.

PR09 Macrophage promotion of anti-androgen resistance in prostate cancer bone disease. Bin-Zhi Qian, MRC Centre for Reproductive Health, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK, Edinburgh, United Kingdom.

PR10 Inhibition of MEK1/2 overcomes resistance to α PD-1 blockade in pancreatic ductal adenocarcinoma through modulation of NETosis in tumor-associated neutrophils. Brian Herbst, Johns Hopkins University School of Medicine, Baltimore, MD, United States.